Impact of Age on Subcutaneous Implantable Cardioverter-Defibrillator in a Large Patient Cohort

Boersma, 2017, Implant and midterm outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: the EFFORTLESS study, J Am Coll Cardiol, 70, 830, 10.1016/j.jacc.2017.06.040 Weiss, 2013, Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator, Circulation, 128, 944, 10.1161/CIRCULATIONAHA.113.003042 Lambiase, 2014, Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD registry, Eur Heart J, 35, 1657, 10.1093/eurheartj/ehu112 Knops, 2020, Subcutaneous or transvenous defibrillator therapy, N Engl J Med, 383, 526, 10.1056/NEJMoa1915932 von Alvensleben, 2019, Subcutaneous implantable cardioverter defibrillator placement in a 5-year-old patient: Modifications for the smallest patients, HeartRhythm Case Rep, 5, 440, 10.1016/j.hrcr.2019.05.004 Reeves, 2015, Implantation of the subcutaneous implantable cardioverter-defibrillator with retroperitoneal generator placement in a child with hypoplastic left heart syndrome, HeartRhythm Case Rep, 1, 176, 10.1016/j.hrcr.2015.01.016 Bardy, 2010, An entirely subcutaneous implantable cardioverter-defibrillator, N Engl J Med, 363, 36, 10.1056/NEJMoa0909545 Gold, 2017, Subcutaneous Implantable Cardioverter-Defibrillator Post-Approval Study: clinical characteristics and perioperative results, Heart Rhythm, 14, 1456, 10.1016/j.hrthm.2017.05.016 Olde Nordkamp, 2012, The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort, J Am Coll Cardiol, 60, 1933, 10.1016/j.jacc.2012.06.053 Bardy, 2005, Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure, N Engl J Med, 352, 225, 10.1056/NEJMoa043399 Moss, 2002, Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction, N Engl J Med, 346, 877, 10.1056/NEJMoa013474 Moss, 1996, Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia, N Engl J Med, 335, 1933, 10.1056/NEJM199612263352601 Burke, 2020, 1-year prospective evaluation of clinical outcomes and shocks: the Subcutaneous ICD Post-Approval Study, J Am Coll Cardiol EP, 6, 1537 Elming, 2017, Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure, Circulation, 136, 1772, 10.1161/CIRCULATIONAHA.117.028829 Barra, 2015, Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations, Europace, 17, 174, 10.1093/europace/euu296 Vetta, 2020, [Implantable cardioverter-defibrillator therapy in primary prevention in the elderly]. Article in Italian, G Ital Cardiol (Rome), 21, 790 Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144 Gray, 1988, A class of K-sample tests for comparing the cumulative incidence of a competing risk, Ann Stat, 16, 1141, 10.1214/aos/1176350951 Friedman, 2022, Longitudinal outcomes of subcutaneous or transvenous implantable cardioverter-defibrillators in older patients, J Am Coll Cardiol, 79, 1050, 10.1016/j.jacc.2021.12.033 Gulletta, 2022, Age-related differences and associated mid-term outcomes of subcutaneous implantable cardioverter defibrillators: a propensity-matched analysis from a multicenter European registry, Heart Rhythm, 19, 1109, 10.1016/j.hrthm.2022.02.029 Gold, 2021, Primary results from the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) trial, Circulation, 143, 7, 10.1161/CIRCULATIONAHA.120.048728 Gasparini, 2017, Long detection programming in single-chamber defibrillators reduces unnecessary therapies and mortality: the ADVANCE III trial, J Am Coll Cardiol EP, 3, 1275 Schwab, 2015, Reduction of inappropriate ICD therapies in patients with primary prevention of sudden cardiac death: DECREASE study, Clin Res Cardiol, 104, 1021, 10.1007/s00392-015-0870-z Kutyifa, 2016, Novel ICD programming and inappropriate ICD therapy in CRT-D versus ICD patients: a MADIT-RIT sub-study, Circ Arrhythm Electrophysiol, 9, 10.1161/CIRCEP.114.001965 Gasperetti, 2021, Long-term complications in patients implanted with subcutaneous implantable cardioverter-defibrillators: real-world data from the extended ELISIR experience, Heart Rhythm, 18, 2050, 10.1016/j.hrthm.2021.07.008 Boersma, 2016, Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction, Heart Rhythm, 13, 157, 10.1016/j.hrthm.2015.08.039 Kleemann, 2007, Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years, Circulation, 115, 2474, 10.1161/CIRCULATIONAHA.106.663807 Botto, 2017, The Italian subcutaneous implantable cardioverter-defibrillator survey: S-ICD, why not?, Europace, 19, 1826, 10.1093/europace/euw337 Knops, 2022, Efficacy and safety of appropriate shocks and antitachycardia pacing in transvenous and subcutaneous implantable defibrillators: analysis of all appropriate therapy in the PRAETORIAN trial, Circulation, 145, 321, 10.1161/CIRCULATIONAHA.121.057816 Schuger, 2021, Reassessing the role of antitachycardia pacing in fast ventricular arrhythmias in primary prevention implantable cardioverter-defibrillator recipients: results from MADIT-RIT, Heart Rhythm, 18, 399, 10.1016/j.hrthm.2020.11.019 Ruwald, 2014, Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial—Reduce Inappropriate Therapy (MADIT-RIT), Circ Arrhythm Electrophysiol, 7, 785, 10.1161/CIRCEP.114.001623 Saeed, 2014, Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study, J Cardiovasc Electrophysiol, 25, 52, 10.1111/jce.12273 Schuger, 2021, Assessment of Primary Prevention Patients Receiving an ICD—Systematic Evaluation of ATP: APPRAISE ATP, Heart Rhythm O2, 2, 405, 10.1016/j.hroo.2021.07.003 Friedman, 2016, Trends and in-hospital outcomes associated with adoption of the subcutaneous implantable cardioverter defibrillator in the united states, JAMA Cardiol, 1, 900, 10.1001/jamacardio.2016.2782 Lambiase, 2022, Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study, Eur Heart J, 43, 2037, 10.1093/eurheartj/ehab921